Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes.
Whether supplementation of curcuminoids decreases serum adipocyte-fatty acid binding protein (A-FABP) level and whether this decrease benefits glucose control is unclear. One-hundred participants (n=50 administered curcuminoids, n=50 administered placebo) from our previous report on the effect of curcuminoids on type 2 diabetes in a 3-month intervention were assessed for levels of serum A-FABP, oxidative stress, and inflammatory biomarkers. Curcuminoids supplementation led to significant decreases in serum A-FABP, C-reactive protein (CRP), tumor necrosis factor-α, and interleukin-6 levels. Curcuminoids supplementation also significantly increased serum superoxide dismutase (SOD) activity. The change in serum A-FABP levels showed positive correlations with changes in levels of glucose, free fatty acids (FFAs), and CRP in subjects supplemented with curcuminoids. Further stepwise regression analysis showed that A-FABP was an independent predictor for levels of FFAs, SOD, and CRP. These results suggest that curcuminoids may exert anti-diabetic effects, at least in part, by reductions in serum A-FABP level. A-FABP reduction is associated with improved metabolic parameters in human type 2 diabetes.
Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, Heilongjiang, China.
Li Xin
LX
Na
The 1st affiliated hospital of Harbin Medical University, Harbin 150081, Heilongjiang, China.
Bo Lin
BL
Yan
Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, Heilongjiang, China.
Shuo
S
Jiang
Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, Heilongjiang, China.
Hong Li
HL
Cui
Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, Heilongjiang, China.
Ying
Y
Li
Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, Heilongjiang, China.
Chang Hao
CH
Sun
D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis*; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D018384:Oxidative Stress / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D015415:Biomarkers; D001786:Blood Glucose; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D007004:Hypoglycemic Agents; D003474:Curcumin